Avaí Bio, Inc.
Category: AI in Healthcare
Emerging biotechnology company developing cell-based therapies for diabetes and age-related diseases via genetically modified cell lines and encapsulation joint ventures. Avaí Bio, Inc. was founded in 2017. The company is led by Chris Winter. Based in Las Vegas, USA. Team size: 1-10. Latest round: Post-IPO. Key investors include GHS Investments.
- Founded
- 2017
- Headquarters
- Las Vegas, USA
- Team size
- 1-10
Value proposition
To provide next-generation, turnkey solutions that enhance compute performance, speed, and storage capacity at a lower total cost of ownership, with a superior environmental sustainability profile.
Products and solutions
AI-managed data centers, High-performance computing systems, Distributed submerged infrastructure solutions, Proprietary AI software platform for data center management, AI-driven resource allocation solution, High-density compute infrastructure, Supercomputer network software
Unique value
The company focuses on developing proprietary AI for managing and optimizing data center performance, security, and resource allocation. It also utilizes distributed submerged infrastructure solutions, suggesting the use of advanced immersion cooling technology.
Target customer
Patients and clinicians in type 1 / insulin-dependent type 2 diabetes and age-related / longevity medicine; biotech and clinical partners for cell therapy development.
Industries served
Biotechnology, Cell Therapy, Diabetes, Age-related / Longevity Medicine, Regenerative Medicine
Technology advantage
Avant's key advantage lies in its AI platform designed for proactive issue detection, predictive maintenance, and continuous optimization of data center operations. The use of immersion cooling technology also offers a superior environmental sustainability profile and potentially lower total cost of ownership.
How they differentiate
Differentiates via JV model pairing capital/strategy with Austrianova encapsulation IP for cell-based diabetes (Insulinova) and longevity (Klothonova) programs, rather than building proprietary AI data-center infrastructure.
Main competitors
UST, Happiest Minds, Endava
Key partnerships
50/50 JV with Austrianova/SGAustria — Insulinova (cell-based diabetes therapy), 50/50 JV with Austrianova/SGAustria — Klothonova (α-Klotho anti-aging cell therapy), Research collaboration: Insulinova with Ospedale San Raffaele (Aug 2026) for encapsulated diabetes cell therapy, Ainnova Tech Vision AI JV (Ai-Nova Acquisition Corp) mutually terminated May 7, 2026
Notable customers
Pre-commercial / JV-stage: Insulinova diabetes program (Austrianova; San Raffaele research collaboration), Klothonova α-Klotho program with Austrianova (GMP master cell bank milestones 2026)
Major milestones
Corporate rebrand: Avant Technologies → Avaí Bio, Inc. (effective Feb 11, 2026); new site avaibio.com, Formed Insulinova JV with Austrianova for cell-based diabetes therapy (Nov 2025), Formed Klothonova JV for α-Klotho therapies; GMP master cell bank production (2026), San Raffaele Hospital research collaboration for encapsulated diabetes cell therapy (Aug 2026), Terminated Ainnova AI healthcare JV (May 2026); terminated GHS $20M ELOC (May 2025)
Growth metrics
OTCQB: AVAI public issuer; ~4 employees (OTC as of Mar 2026); pre-revenue biotech with ongoing losses; growth via Insulinova/Klothonova JV milestones (GMP MCB, San Raffaele RCA) rather than AI data-center buildout.
Market positioning
Positioned as an emerging OTCQB biotechnology company focused on cellular therapies for diabetes and age-related disease through joint ventures and licensing, not as an AI infrastructure provider.
Geographic focus
The company's primary geographic focus is the United States, with its headquarters in Las Vegas, Nevada, and a new data center being built in Milwaukee, Wisconsin.
Patents and IP
The company frequently refers to its 'proprietary AI,' indicating internal intellectual property. However, no specific public patents have been found.
About Chris Winter
Chris Winter has over 35 years of experience in investment banking and commodities (private placements, public offerings, M&A). Held Series 3/7/63 licenses (1987–1994); founded a private investment banking consulting firm in 1995; has participated in raising over $70M. Former CEO/President of Innovative Holdings Alliance, Inc. (through Feb 2024).
More AI in Healthcare companies
Official website: https://www.avaibio.com